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Abstract
Aims/hypothesis Glucose-dependent insulinotropic polypep-
tide (GIP) and xenin, regulatory gut hormones secreted from
enteroendocrine K cells, exert important effects on metabo-
lism. In addition, xenin potentiates the biological actions of
GIP. The present study assessed the actions and therapeutic
utility of a (DAla2)GIP/xenin-8-Gln hybrid peptide, in com-
parison with the parent peptides (DAla2)GIP and xenin-8-Gln.
Methods Following confirmation of enzymatic stability, in-
sulin secretory activity of (DAla2)GIP/xenin-8-Gln was
assessed in BRIN-BD11 beta cells. Acute and persistent
glucose-lowering and insulin-releasing effects were then
examined in vivo. Finally, the metabolic benefits of twice
daily injection of (DAla2)GIP/xenin-8-Gln was determined
in high-fat-fed mice.
Results All peptides significantly (p<0.05 to p<0.001) en-
hanced in vitro insulin secretion from pancreatic clonal BRIN-
BD11 cells, with xenin (and particularly GIP)-related signal-
ling pathways, being important for this action. Administration
of (DAla2)GIP or (DAla2)GIP/xenin-8-Gln in combination
with glucose significantly (p<0.05) lowered blood glucose
and increased plasma insulin in mice, with a protracted re-
sponse of up to 4 h. All treatments elicited appetite-
suppressive effects (p < 0.05), particularly (DAla2)GIP/
xenin-8-Gln and xenin-8-Gln at elevated doses of 250 nmol/
kg. Twice-daily administration of (DAla2)GIP/xenin-8-Gln
or (DAla2)GIP for 21 days to high-fat-fed mice returned
circulating blood glucose to lean control levels. In addi-
tion, (DAla2)GIP/xenin-8-Gln treatment significantly
(p< 0.05) reduced glycaemic levels during a 24 h glucose
profile assessment. Neither of the treatment regimens had
an effect on body weight, energy intake or circulating
insulin concentrations. However, insulin sensitivity was
significantly (p < 0.001) improved by both treatments.
Interestingly, GIP-mediated glucose-lowering (p < 0.05)
and insulin-releasing (p < 0.05 to p < 0.01) effects were
substantially improved by (DAla2)GIP and (DAla2)GIP/
xenin-8-Gln treatment. Pancreatic islet and beta cell area
(p < 0.001), as well as pancreatic insulin content
(p< 0.05), were augmented in (DAla2)GIP/xenin-8-Gln-
treated mice, related to enhanced proliferation and de-
creased apoptosis of beta cells, whereas (DAla2)GIP
evoked increases (p< 0.05 to p< 0.01) in islet number.
Conclusions/interpretation These studies highlight the clear
potential of GIP/xenin hybrids for the treatment of type 2
diabetes.
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A defect in the postprandial insulin-secretory incretin re-
sponse, mediated by the gut hormones glucagon-like pep-
tide-1 (GLP-1) and glucose-dependent insulinotropic peptide
(GIP), is a specific pathophysiological characteristic of type 2
diabetes [1]. The main impairments are recognised as reduced
postprandial GLP-1 secretion and defective GIP receptor sig-
nalling [1]. The inadequacy in the GLP-1 arm of the incretin
effect can be easily overcome through administration of exog-
enous GLP-1, which significantly amplifies circulating con-
centrations [2, 3]. In contrast, pharmacological augmentation
of circulating GIP levels fails to evoke an effective increase in
insulin secretion in patients with type 2 diabetes [4]. As such,
it seems unlikely that stand-alone GIP-based drugs would
have therapeutic value for type 2 diabetes. Notwithstanding
this, strategies to overcome defective GIP action in type 2
diabetes would be of considerable interest.
Near normalisation of blood glucose levels has been shown
to restore the insulin-secretory effect of GIP in both animal
models of type 2 diabetes [5] and in humans [6] with this
condition, providing evidence that defective GIP receptor sig-
nalling is reversible. In addition, co-administration of GIP
with a sulfonylurea restores pancreatic beta cell sensitivity to
GIP [7], although this could be linked to uncoupling of
incretin glucose dependency by sulfonylureas [8]. More en-
couraging, recent studies have highlighted the possibility that
xenin, a hormone co-secreted with GIP from a subset of
enteroendocrine K cells, could amplify the insulin-secretory
response of GIP [9]. In agreement, observations from our
laboratory and others confirm the GIP-potentiating effects of
xenin under normal and type 2 diabetes conditions [10–13].
Furthermore, there is also evidence to suggest that xenin acts
as a satiety hormone in animals [10, 14–17] and humans [18].
As such, therapeutic interventions that combine the biological
actions of xenin and GIP, and potentially restore GIP action in
type 2 diabetes, would have particularly exciting potential.
There has been a recent upsurge in interest focused on gener-
ating designer hybrid peptides that can modulate multiple reg-
ulatory peptide hormone receptor pathways [19–22].
Successful generation of hybrid peptides has been achieved
through fusion of the key bioactive amino acid sequences of
the parent peptides [19–22]. This increases the therapeutic
applicability of gut-hormone-based drugs by facilitating for-
mulation and dosing with a single molecule, rather than co-
injection of separate parent peptide forms. For xenin, the nat-
urally occurring C-terminal fragment, known as xenin-8, re-
tains biological activity at the level of the endocrine pancreas
[13, 23]. Moreover, we have also shown that a stable analogue
of xenin-8, namely xenin-8-Gln, is biologically active and has
a spectrum of beneficial metabolic effects in vitro and in vivo
[24]. For GIP, the first 14 N-terminal amino acid residues
contain the bioactive domain important for insulin-secretory
function [25, 26]. Based on this knowledge, we constructed a
novel GIP/xenin hybrid peptide, (DAla2)GIP/xenin-8-Gln, by
linking GIP(1-14) to xenin-8-Gln, retaining the regions of
each peptide known to be important for biological activity
(see electronic supplementary material [ESM] Table 1).
Importantly, since GIP is a substrate for dipeptidyl
peptidase-4 (DPP-4) [27], the hybrid peptide includes substi-
tution of the naturally occurring alanine L isomer residue by a
D isomer at position 2 [28, 29]. The results reveal that GIP/
xenin hybrid molecules require further consideration as a
treatment option for type 2 diabetes.
Methods
Peptide synthesisAll peptides (ESMTable 1) were purchased
from GL Biochem (Shanghai, China; greater than 95% puri-
ty). Peptides were characterised in-house using HPLC and
matrix-assisted laser desorption ionisation time-of-flight
(MALDI-TOF) mass spectrometry (ESM Table 2), as de-
scribed previously [29].
Assessment of DPP-4 degradation Peptide (20 μg) DPP-4
degradation profiles (5 μl purified DPP-4, 5 mU; Sigma-
Aldrich, UK) were assessed as described previously [29].
Xenin-based peptides have been shown to be resistant to
DPP-4 [10, 24].
In vitro insulin secretion BRIN-BD11 cells were used to
assess the insulin-releasing activity of test peptides, as de-
scribed previously [30]. This hybrid cell line (ECACC
10033003) was originally generated in-house by electrofusion
of a primary culture of New England Deaconess Hospital
(NEDH) rat pancreatic islets with RINm5F (a cell line derived
from an NEDH rat insulinoma), and has been mycoplasma
eradicated. For details of experimental conditions please see
ESM Methods. Insulin was measured by radioimmunoassay
[31].We assessed the impact of GIP and neurotensin receptors
on (DAla2)GIP/xenin-8-Gln-induced insulin secretion in
BRIN-BD11 cells. Cells were incubated in 5.6 mmol/l glucose
with (DAla2)GIP/xenin-8-Gln (10−6 mol/l) alone or in combi-
nation with the GIP receptor antagonist GIP(6-30)Cex-
K40[Pal] [32] (where Pal is palmitate) or the neurotensin re-
ceptor antagonist SR142948A (Sigma, Poole, UK), and
insulin secretion determined as described above. In addition,
to determine mechanisms, intracellular Ca2+ was also
measured in BRIN-BD11 cells following treatment with
test peptides (10−6 mol/l), using a Flexstation scanning
fluorometer (FLIPR Calcium 5 assay kit; Molecular
Devices, Sunnyvale, CA, USA), as described previously [10].
Animals Acute and persistent dose-dependent animal studies
were conducted in male albino NIH outbred Swiss mice
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(Envigo, Huntingdon, UK), that were derived from a nucleus
colony obtained from the National Institutes of Health,
Bethesda, Maryland. Longer-term experiments were conduct-
ed with male high-fat-fed NIH Swiss mice. For further details
of mice age and maintenance please see ESM.
Acute in vivo effects in lean mice Specific information on
acute feeding, glucose homeostasis and insulin-secretory stud-
ies is given in ESMMethods. To assess the impact of GIP and
neurotensin receptor activation on (DAla2)GIP/xenin-8-Gln-
induced glucose-lowering and insulin-secretory actions in
mice, (DAla2)GIP/xenin-8-Gln was administered by i.p. injec-
tion (25 nmol/kg body weight) in combination with glucose
(18 mmol/kg) in the absence and presence of GIP(6-30)Cex-
K40[Pal] and SR142948A (both at 25 nmol/kg), and glucose
and insulin were measured as described above. In a final series
of experiments, test peptides (25 nmol/kg) or saline vehicle
(0.9% wt/vol. NaCl) were injected 4 h before a glucose load
(18 mmol/kg) in non-fasted mice and blood glucose and plas-
ma insulin measured as above.
Subchronic in vivo studies in high-fat-fed mice Twice-daily
(09:30 and 17:30 hours) i.p. injections of saline vehicle,
(DAla2)GIP or (DAla2)GIP/xenin-8-Gln hybrid (both at
25 nmol/kg) were administered for 21 days in high-fat-fed
mice. Energy intake and body weight were monitored daily
and non-fasting blood glucose and plasma insulin concentra-
tions were assessed at 3 day intervals. On day 21, a non-fasted
24 h glucose profile was conducted. At the end of the treat-
ment period, i.p. glucose tolerance (18 mmol/kg), biological
response to GIP (18 mmol/kg glucose in combination with
native GIP [25 nmol/kg], i.p.) and insulin sensitivity (15 U/
kg; i.p.) tests were performed. Terminal analysis included
measurement of total body fat and lean mass by dual-energy
X-ray absorptiometry (DEXA) scanning (Piximus
Densitometer; Inside Outside Sales, Fitchburg, WI, USA)
and extraction of pancreatic tissue for analysis as detailed
below.
Immunohistochemistry Pancreas tissue was excised, divided
longitudinally and either snap frozen for extraction of insulin
using acid ethanol (5 ml/g), as described previously [22], or
processed for immunohistochemical examination.
Immunohistochemistry was performed as described previous-
ly [33]. For specific details, please see ESM Methods.
Biochemical analysis Blood samples were collected from the
cut tip on the tail vein of conscious mice into chilled fluoride/
heparin glucose micro-centrifuge tubes (Sarstedt, Numbrecht,
Germany). Blood glucose was measured directly using a
hand-held Ascencia Contour blood glucose meter (Bayer
Healthcare, Newbury, UK). Plasma and pancreatic insulin
was assayed by a modified dextran-coated charcoal radioim-
munoassay [31].
Statistical analysis Statistical analysis was performed using
GraphPad PRISM (La Jolla, CA, USA; version 5). For
in vitro, islet histology and pancreatic insulin content studies,
all samples were numbered and blinded. For acute and sub-
chronic metabolic tests, there was no blinding. There were no
inclusion and exclusion criteria applied. Results are expressed
as means±SEM and data were compared using repeated mea-
sures ANOVA followed by the Student–Newman–Keuls post
hoc test. Groups of data were considered to be significantly
different if p<0.05.
Results
In vitro studies In contrast to native GIP, (DAla2)GIP/xenin-
8-Gln and (DAla2)GIP remained fully intact when incubated
in the presence of DPP-4 for up to 12 h (ESM Table 2). All
peptides significantly (p<0.05 to p<0.001) stimulated insulin
secretion from BRIN-BD11 cells at a concentration of
10−6 mol/l (Fig. 1a, b). Only (DAla2)GIP evoked a significant
(p<0.01 to p<0.001) increase in insulin release at 10−8 mol/l
when compared with respective glucose controls (Fig. 1a, b).
As expected, the GIP receptor inhibitor GIP(6-30)Cex-
K40[Pal] completely annulled (DAla2)GIP-mediated elevation
of insulin secretion, while the neurotensin receptor inhibitor
SR142948A had a similar, but less prominent, effect on xenin-
8-Gln (Fig. 1c). As such, insulin concentrations were still
significantly elevated (p < 0.05) following co-culture of
xenin-8-Gln and SR142948A when compared with
5.6 mmol/l glucose control (Fig. 1c). The insulinotropic effect
of (DAla2)GIP/xenin-8-Gln was completely inhibited
(p<0.001) by GIP(6-30)Cex-K40[Pal] and partially reversed
(p< 0.05) by SR142948A (Fig. 1c). Neither, (DAla2)GIP,
xenin-8-Gln nor (DAla2)GIP/xenin-8-Gln had any effect on
intracellular Ca2+ concentrations (Fig. 1d).
Acute in vivo food-intake studies At 25 nmol/kg,
(DAla2)GIP/xenin-8-Gln induced a significant (p<0.05) re-
duction in food intake at 30min post injection when compared
with saline controls (Fig. 1e). None of the peptides had signif-
icant appetite-suppressive effects when administered at
100 nmol/kg (Fig. 1f). At a supraphysiological dose of
250 nmol/kg, all peptides except (DAla2)GIP induced signif-
icant (p<0.05 to p<0.01) reductions in food intake at 180min
post injection (Fig. 1g). In addition, at 250 nmol/kg, the
appetite-suppressive effect of xenin was significantly
(p<0.05) superior to control mice at 90 min post injection,
while xenin-8-Gln and (DAla2)GIP/xenin-8-Gln also evoked
significant (p<0.05) reductions in food intake at 120 min
(Fig. 1g).
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Acute and persistent glucose-lowering and insulin-
releasing effects in lean mice Administration of xenin-8-
Gln, (DAla2)GIP or (DAla2)GIP/xenin-8-Gln concomitantly
with glucose resulted in significantly (p<0.05) lowered blood
glucose values at 30 min post injection, culminating in signif-
icantly (p<0.05) decreased overall AUC blood glucose values
when compared with controls (Fig. 2a). (DAla2)GIP also in-
duced a significant (p<0.05) reduction in blood glucose levels
15 min post injection (Fig. 2a). Corresponding glucose-
induced plasma insulin concentrations were not altered be-
tween groups in terms of individual values, although overall
glucose-stimulated plasma insulin levels were significantly
(p<0.05) increased in all treatment groups compared with
controls (Fig. 2b). The beneficial (p<0.01) acute glucose-
lowering effect of (DAla2)GIP/xenin-8-Gln was blocked by
both GIP(6-30)Cex-K40[Pal] and SR142948A (Fig. 2c),
whereas only GIP(6-30)Cex-K40[Pal] impaired (DAla2)GIP/
xenin-8-Gln-induced insulinotropic actions (Fig. 2d). When
administered 4 h prior to a glucose load, xenin-8-Gln was
devoid of glucose-lowering or insulin-releasing effects
(Fig. 2e, f). However, when administered 4 h previously, both
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reduced the overall AUC for blood glucose (p<0.05) and
increased plasma insulin AUC (p<0.05) following a glucose
challenge (Fig. 2e, f).
Effects of twice-daily administration of (DAla2)GIP and
(DAla2)GIP/xenin-8-Gln on energy intake, body weight,
non-fasted blood glucose and plasma insulin in high-fat-
fed mice Twice-daily administration of (DAla2)GIP or
(DAla2)GIP/xenin-8-Gln for 21 days to high-fat-fed mice
had no significant effect on cumulative energy intake or body
weight compared with high-fat-fed controls (Fig. 3a, c). In
addition, total body fat and leanmass were also unaltered after
the 21 day regimen (Fig. 3b). However, all high-fat fed mice
exhibited significantly increased (p<0.05 to p<0.001) body
weight and cumulative energy intake compared with lean con-
trols (Fig. 3a, c). Non-fasting blood glucose levels progres-
sively declined in (DAla2)GIP/xenin-8-Gln-treated high-fat
fed mice over the 21 days, being significantly (p<0.05 to
p<0.01) reduced on observation days 3, 6 and 15 compared
with levels in control high-fat mice (Fig. 3d). Both
(DAla2)GIP- and (DAla2)GIP/xenin-8-Gln-treated mice had
glucose levels that were not significantly different from lean
controls from day 12 onwards (Fig. 3d). Analysis of non-
fasting 24 h glucose profile on day 21 revealed that
(DAla2)GIP/xenin-8-Gln treated mice had similar blood glu-
cose levels to lean controls at each observation point and sig-
nificantly (p<0.05) reduced levels compared with high-fat-
fed controls at 17:00 hours (Fig. 3e). Blood glucose levels in
(DAla2)GIP-treated mice were also reduced, but not to the
same extent as in (DAla2)GIP/xenin-8-Gln mice (Fig. 3e).
Circulating plasma insulin levels were generally elevated in
all high-fat-fed mice compared with lean controls (Fig. 3f).
Mice treated twice daily with either (DAla2)GIP or
(DAla2)GIP/xenin-8-Gln did have reduced plasma insulin
levels compared with high-fat-fed controls on day 21 but the
difference did not reach statistical significance (Fig. 3f).
Effects of twice-daily administration of (DAla2)GIP and
(DAla2)GIP/xenin-8-Gln on glucose tolerance and meta-
bolic response to GIP in high-fat-fed mice Treatment with
(DAla2)GIP or (DAla2)GIP/xenin-8-Gln for 21 days reduced
overall AUC for blood glucose levels of high-fat-fed mice fol-
lowing a glucose load but the difference failed to reach statisti-
cal significance (Table 1). Similarly, glucose-stimulated plasma
insulin AUCs were reduced non-significantly by (DAla2)GIP
or (DAla2)GIP/xenin-8-Gln treatment compared with high-fat
controls (Table 1). All high-fat-fed mice had a significantly
(p<0.05 to p<0.001) increased glycaemic excursion and over-
all insulin-secretory response compared with lean controls
(Table 1). As illustrated in Table 1, (DAla2)GIP and
(DAla2)GIP/xenin-8-Gln treatment significantly (p<0.05) im-
proved the glucose-lowering and insulin-releasing actions of
native GIP; overall blood glucose AUC values were significant-
ly (p<0.05) decreased by 36% and 30%, respectively, com-
pared with saline-treated control. Moreover, AUCs for
glycaemic values were not different when compared with lean
controls in response to administration of GIP in combination
with glucose (Table 1). Corresponding GIP-induced elevations
of plasma insulin concentrations were also significantly
(p < 0.05 to p < 0.01) augmented in (DAla2)GIP- and
(DAla2)GIP/xenin-8-Gln-treated high-fat-fed mice compared
with high-fat-fed controls (Table 1).
Effects of twice-daily administration of (DAla2)GIP and
(DAla2)GIP/xenin-8-Gln on insulin sensitivity and pancre-
atic insulin content in high-fat fed mice Individual blood
glucose levels were reduced, albeit non-significantly, in
(DAla2)GIP- and (DAla2)GIP/xenin-8-Gln-treated high-fat-
fed mice following administration of exogenous insulin
(Fig. 4a). However, the overall glucose-lowering effect of
insulin was significantly (p < 0.001) improved in
(DAla2)GIP- and (DAla2)GIP/xenin-8-Gln-treated mice
compared with control high-fat mice (Fig. 4b). The pancre-
atic insulin content of (DAla2)GIP/xenin-8-Gln-treated
mice was augmented (p< 0.05) compared with that of lean
controls but was not significantly different from that of
high-fat controls (Fig. 4c). In contrast, the pancreatic insu-
lin content of (DAla2)GIP-treated mice was similar to that
of lean control mice (Fig. 4c).
Fig. 1 Effects of peptides on insulin release and intracellular Ca2+
concentrations in BRIN-BD11 cells and on cumulative food intake in
lean control mice. (a, b) BRIN-BD11 cells were incubated (20 min)
with test peptides in the presence of 5.6 mmol/l glucose (a) or
16.7 mmol/l glucose (b). Light-grey bars, glucose controls; white bars,
xenin-8-Gln; dark-grey bars, (DAla2)GIP; black bars, (DAla2)GIP/xenin-
8-Gln. (c) Effects of the GIP and neurotensin receptor antagonists, GIP(6-
30)Cex-K40[Pal] and SR142948A, respectively, on (DAla2)GIP-, xenin-
8-Gln- and (DAla2)GIP/xenin-8-Gln-mediated (20 min) insulin release in
BRIN-BD11 cells. White bars, incubation in 5.6 mmol/l glucose alone;
black bars, glucose plus GIP(6-30)Cex-K40[Pal] (10−6 mol/l); grey bars,
glucose plus SR142948A (10−6 mol/l). (d) BRIN-BD11 cells were
incubated with 5.6 mmol/l glucose in the presence of test peptides
(10−6 mol/l) and intracellular Ca2+ concentrations were assessed over a
5 min period, with alanine (10 mmol/l) as positive control. AUC (0–
300 s) data is shown in the inset. Black circles and light-grey bars,
5.6 mmol/l glucose control; black squares and striped bars, 10 mmol/l
alanine; white circles and white bars, xenin-8-Gln; white squares and
dark-grey bars, (DAla2)GIP; black triangles and black bars,
(DAla2)GIP/xenin-8-Gln. (e–g) Cumulative food intake was measured
after i.p. injection of peptides at 25 (e), 100 (f) and 250 nmol/kg (g) in
overnight-fasted (18 h) lean control mice. Black bars, saline control;
diagonally striped bars, xenin-8; dark-grey bars, xenin-25; horizontally
striped bars, xenin-8-Gln; light-grey bars, (DAla2)GIP; white bars,
(DAla2)GIP/xenin-8-Gln. Values represent means ± SEM (n = 8).
*p < 0.05, **p < 0.01 and ***p < 0.001 compared with respective
glucose (a–d) or saline controls (e–g); †p < 0.05 and †††p < 0.001
compared with incubations in the absence of GIP or neurotensin
receptor antagonists, as appropriate
R
Diabetologia (2017) 60:541–552 545
Effects of twice-daily administration of (DAla2)GIP and
(DAla2)GIP/xenin-8-Gln on pancreatic islet histology in
high-fat-fed mice Representative images of pancreatic islets
from each mouse group are shown in Fig. 5a–d. High-fat-fed
mice had significantly (p<0.01) increased islet area compared
with lean controls (Fig. 5e), giving rise to significant (p<0.01)
increases in both beta and alpha cell areas (Fig. 5f, g). Treatment
with (DAla2)GIP had no significant effect on overall pancreatic
islet area or beta cell area but resulted in decreased (p<0.001)
alpha cell area compared with high-fat-fed controls (Fig. 5e–g).
Similarly, 21 days of twice-daily treatment with (DAla2)GIP/
xenin-8-Gln significantly (p<0.001) reduced pancreatic alpha
cell area compared with high-fat-fed controls (Fig. 5g). It also
increased (p<0.001) pancreatic islet and beta cell area compared
with lean controls (Fig. 5e, f). The number of islets per mm2was
significantly (p<0.05 to p<0.01) augmented in (DAla2)GIP-
treated mice compared with all other groups (Fig. 5h). This
effect appeared to be related to an increase in number of
small-sized islets (Fig. 5i). Thus, high-fat feeding significantly
(p<0.001) decreased the number of small islets and increased
the number of large islets, compared with lean controls (Fig. 5i).
(DAla2)GIP/xenin-8-Gln-treated high-fat-fed mice also had a
decreased (p<0.001) number of small- andmedium-sized islets,
and fewer (p<0.001) large islets, when compared with lean
controls (Fig. 5i). Representative images of Ki67 and TUNEL
immunostained pancreatic islets from each group of mice are
shown in Fig. 6a–h. Proliferation and apoptosis rates of pancre-
atic islet cells appeared to be relatively high in this strain of
mouse. The rate of beta cell proliferation in (DAla2)GIP/xenin-
8-Gln-treated high-fat-fed mice was significantly (p<0.05 to
p<0.001) increased when compared with the rate in all other
groups (Fig. 6i). In addition, the frequency of beta cell





























































































































































































































































































Fig. 2 Acute and persistent glucose-lowering and insulin-releasing ef-
fects of (DAla2)GIP, xenin-8-Gln and (DAla2)GIP/xenin-8-Gln in lean
control mice. (a, b) Blood glucose (a) and plasma insulin (b) concentra-
tions were measured before and after i.p. injection of glucose alone
(18 mmol/kg) or in combination with peptides (each at 25 nmol/kg) in
non-fasted mice. AUCs are shown in insets. (c, d) Overall AUCs for
blood glucose (c) and plasma insulin (d) were measured before and after
i.p. injection of (DAla2)GIP/xenin-8-Gln. (25 nmol/kg) in combination
with glucose (18 mmol/kg) in the absence or presence of GIP(6-30)Cex-
K40[Pal] and SR142948A (both at 25 nmol/kg) in non-fasted mice. (e, f)
Blood glucose (e) and plasma insulin (f) concentrations were measured
following an i.p. glucose load (18 mmol/kg) in non-fasted mice injected
with saline vehicle or peptides (each at 25 nmol/kg) 4 h previously. AUCs
are shown in insets. Black circles and white bars, glucose alone (a–d) or
saline control (e, f); white triangles and dark-grey bars, glucose (a, b) or
saline (e, f) in combination with (DAla2)GIP; white squares and light-
grey bars, glucose (a, b) or saline (e, f) in combination with xenin-8-Gln;
black squares and black bars, glucose (a–d) or saline (c, d) in combination
with (DAla2)GIP/xenin-8-Gln; horizontal striped bars, (DAla2)GIP/
xenin-8-Gln in combination with GIP(6-30)Cex-K40[Pal]; diagonally
striped bars, (DAla2)GIP/xenin-8-Gln in combination with SR142948A.
Values represent means ± SEM for 7 or 8 mice. *p < 0.05 and **p< 0.01
compared with glucose alone (a, b) or saline control (c, d); †p< 0.05 and
††p< 0.01 compared with (DAla2)GIP/xenin-8-Gln group
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apoptosis was significantly (p < 0.01) decreased in
(DAla2)GIP- and (DAla2)GIP/xenin-8-Gln-treated high-fat-
fed mice compared with high-fat-fed controls, and was similar
to levels in lean control mice (Fig. 6j).




























































































































































































































Fig. 3 Effects of twice-daily administration of (DAla2)GIP and
(DAla2)GIP/xenin-8-Gln on body weight, body composition, cumulative
energy intake, non-fasted blood glucose, 24 h blood glucose profile and
non-fasted plasma insulin in high-fat-fed mice. (a, c, d, f) Variables were
measured for 3 days before and 21 days during (indicated by black hor-
izontal line) twice-daily treatment with saline vehicle, (DAla2)GIP or
(DAla2)GIP/xenin-8-Gln hybrid (each at 25 nmol/kg). (b, e) Total fat
and lean mass (b) and 24 h glucose profile (e) were assessed on day 21.
Arrows indicate timing of normal twice-daily injections. White squares
and light-grey bars, saline control; white circles and dark-grey bars,
(DAla2)GIP; black circles and black bars, (DAla2)GIP/xenin-8-Gln; black
triangles and white bars, lean control. Values represent means ± SEM for
6–8 mice. *p< 0.05, **p< 0.01 and ***p < 0.001 compared with high-
fat-fed controls. †p< 0.05, ††p< 0.01 and †††p < 0.001 comparedwith lean
controls
Table 1 Effects of twice-daily





and insulin-secretory actions in
high-fat-fed mice













High-fat saline control 2062.0 ± 121.2 16,377± 3063 16,18.9 ± 148.1 9770± 2024
(DAla2)GIP 1714.7 ± 138.6† 11,253 ± 1590† 1029.5 ± 138.0* 20,308± 3805**,†††
(DAla2)GIP/xenin-8-Gln 1757.3 ± 154.6† 8423 ± 1121† 1130.1 ± 143.9* 17,741± 4016*,††
Lean control 1080.5 ± 85.7*** 4237 ± 232.6* 787.4 ± 54.2** 3611 ± 411.9
Values represent means ± SEM for 6–8 mice. AUC values (0–105 min) for blood glucose and plasma insulin are
shown
Tests were conducted after twice-daily treatment with saline vehicle, (DAla2 )GIP or (DAla2 )GIP/xenin-8-Gln
(each at 25 nmol/kg) for 21 days. For glucose tolerance test, blood glucose and plasma insulin concentrations were
measured before and 15, 30, 60 and 105min after i.p injection of glucose (18mmol/kg). For metabolic response to
GIP, blood glucose and plasma insulin concentrations were measured before and 15, 30, 60 and 105 min after i.p
injection of glucose (18 mmol/kg) in combination with GIP (25 nmol/kg). All studies were conducted in mice
fasted for 18 h
*p< 0.05, **p< 0.01 and ***p< 0.001 compared with high-fat controls; † p< 0.05, †† p< 0.01 and ††† p< 0.001
compared with lean controls
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Discussion
Despite encouraging preclinical data and the success of DPP-4
inhibitors [34, 35], progression of enzyme-resistant GIP-based
drugs to the type 2 diabetes clinic is lacking. Therefore, in the
present study we have evaluated the biological actions and

































































































































































Fig. 5 Effects of twice-daily administration of (DAla2)GIP and
(DAla2)GIP/xenin-8-Gln on pancreatic histology. (a–d) Representative
images of islets showing insulin (red) and glucagon (green) immunore-
activity from pancreatic tissues extracted from high-fat-fed saline control
mice (a), (DAla2)GIP- (b) and (DAla2)GIP/xenin-8-Gln-treated high-fat-
fedmice (c) and lean control mice (d). (e–i) Variables were assessed using
CellF image analysis software after 21 days of twice-daily i.p injections of
saline vehicle or peptides (each at 25 nmol/kg) in high-fat-fed mice.
Light-grey bars, saline control; dark-grey bars, (DAla2)GIP; black bars,
(DAla2)GIP/xenin-8-Gln; white bars, lean control (e–h). White bars,
small islets (<10,000 μm2); grey bars, medium islets (10,000–
25,000 μm2); black bars, large islets (>25,000 μm2) (i). Values are
means ± SEM of 6–8 mice. Scale bar, 50 μm. *p < 0.05, **p< 0.01 and
***p < 0.001 compared with high-fat-fed controls. †p < 0.05 and
†††p < 0.001 compared with lean controls; ‡‡p < 0.01 and ‡‡‡p < 0.001
compared with the (DAla2)GIP group
a b c

































































































Fig. 4 Effects of twice-daily administration of (DAla2)GIP and
(DAla2)GIP/xenin-8-Gln on insulin sensitivity and pancreatic insulin
content in high-fat-fed mice. Insulin (15 U/kg) was given by i.p. injection
(t = 0) in non-fasted mice following 21 days treatment with saline vehicle,
(DAla2)GIP or (DAla2)GIP/xenin-8-Gln hybrid (each at 25 nmol/kg).
Blood glucose was measured (a), area above the curve (AAC) was cal-
culated using identical baseline subtraction for each group (b) and
pancreatic insulin content was measured by RIA (c). White squares and
light-grey bars, saline control; white circles and dark-grey bars,
(DAla2)GIP; black circles and black bars, (DAla2)GIP/xenin-8-Gln; black
triangle and white bars, lean control. Values represent means ± SEM for
6–8mice. *p< 0.05, **p< 0.01 and ***p < 0.001 compared with high-fat
controls; †p < 0.05 compared with lean controls
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In harmony with previous studies [28, 29], (DAla2)GIP and
the hybrid peptide (DAla2)GIP/xenin-8-Gln were completely re-
sistant to degradation byDPP-4, indicating that the N-terminal D-
Ala2 modification employed effectively masked the DPP-4 bind-
ing site. As expected, the parent peptides, (DAla2)GIP and xenin-
8-Gln, stimulated insulin release from clonal pancreatic BRIN-
BD11 beta cells at physiological and elevated glucose concen-
trations [24, 29]. To determine the influence of both GIP and
xenin pathways on induction of bioactivity by (DAla2)GIP/
xenin-8-Gln, we utilised the specific GIP receptor antagonist
GIP(6-30)Cex-K40[Pal] [32] and the commercially available
neurotensin receptor antagonist, SR142948A. Reassuringly,
(DAla2)GIP/xenin-8-Gln was equally effective in vitro as an in-
sulin secretagogue as either of the parent peptides. Its
insulinotropic effects appeared to be more dependent on activa-
tion of GIP receptor-related cell signalling pathways, when com-
pared with xenin. In full agreement, the acute in vivo
insulinotropic actions of (DAla2)GIP/xenin-8-Gln were also
chiefly dependent upon activation of GIP receptor pathways.
Interestingly, the acute glucose-lowering actions of
(DAla2)GIP/xenin-8-Gln appeared to be associated with activa-
tion of both GIP and xenin pathways, suggesting possible
insulin-independent glucose-lowering effects of xenin [12].
However, the main effect of the xenin component of
(DAla2)GIP/xenin-8-Gln likely relates to enhancement of GIP-
mediated biological actions, as demonstrated here and previously
[10, 11]. Full clarification of the mechanism of (DAla2)GIP/
xenin-8-Gln-induced insulin release is necessary, but similar
(DAla2)GIP/xenin-8-Gln-induced acute insulin-secretory effects
were also noted in lean control mice, confirming biological effi-
cacy. Our previous studies using clonal beta cells have shown
that (DAla2)GIP activates adenylate cyclase pathways, whereas
xenin-based peptides likely operate through the action of phos-
pholipase C [10]. Further to this, we have shown that neither
(DAla2)GIP/xenin-8-Gln nor its parent peptides significantly af-
fected intracellular Ca2+ levels in BRIN-BD11 beta cells.
In accordance with preserved bioactivity of the hybrid pep-
tide, we observed satiety effects of (DAla2)GIP/xenin-8-Gln
even at the lowest dose examined and especially at elevated
doses. This is in agreement with previous findings suggesting
i j
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Fig. 6 Effects of twice-daily administration of (DAla2)GIP and
(DAla2)GIP/xenin-8-Gln on beta cell proliferation and apoptosis. (a–d)
Representative images showing insulin (green) and Ki67 (red, indicated
by arrows) in islets from high-fat-fed saline control mice (a), (DAla2)GIP-
(b) and (DAla2)GIP/xenin-8-Gln-treated high-fat-fed mice (c) and lean
control mice (d). (e–h) Representative images showing insulin (red) and
TUNEL (green, indicated by arrows) immunoreactivity in islets from
high-fat-fed saline control mice (e), (DAla2)GIP- (f) and (DAla2)GIP/
xenin-8-Gln-treated high-fat-fed mice (g) and lean control mice (h). (i,
j) Quantification of beta cell proliferation (i) and apoptosis frequency (j)
expressed as a percentage of beta cells analysed. Light-grey bars, saline
control; dark-grey bars, (DAla2)GIP; black bars, (DAla2)GIP/xenin-8-
Gln; white bars, lean control. Approximately 5000 beta cells per experi-
mental group were counted. Values are means ± SEM of 6–8 mice. Scale
bar, 50 μm. **p < 0.01 compared with high-fat-fed controls; †††p< 0.001
compared with lean controls; ‡p< 0.05 compared with (DAla2)GIP group
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that elevated doses of xenin are required to impart significant
appetite-suppressive activity, whereas lower doses have ben-
eficial metabolic effects [10, 13]. The persistence of the met-
abolic actions of (DAla2)GIP/xenin-8-Gln was then assessed.
Even 4 h after a single injection of (DAla2)GIP/xenin-8-Gln or
(DAla2)GIP, glucose-lowering and insulin-releasing actions
were clearly evident. This presumably relates to enhanced
enzymatic stability of (DAla2) modified GIP-forms and corre-
sponds well with the findings of other studies [28, 29].
Development of a specific assay to directly measure
(DAla2)GIP/xenin-8-Gln in plasma would be useful to deter-
mine the pharmacokinetic profile of the hybrid peptide.
Moreover, methodology such as peptide acylation or
PEGylation may help to extend the biological half-life of
(DAla2)GIP/xenin-8-Gln [29, 36]. Notably, the biological ef-
fects of (DAla2)GIP/xenin-8-Gln were equal, or indeed en-
hanced, when compared with either parent peptide administered
at the same dose. This indicates that the hybrid peptide still fully
retained the ability to activate GIP- and xenin-related cellular
signalling pathways involved in glucose homeostasis, insulin
secretion and appetite suppression [13, 29]. Taken together,
these data provided a strong basis for the subsequent 21 day
twice-daily injection regimen conducted in high-fat-fed mice.
Chronic treatment of high-fat-fed mice with (DAla2)GIP
resulted in sustained and significant reductions of circulating
blood glucose levels, both in terms of individual observation
points and during assessment of a 24 h blood glucose profile
[28, 29]. Crucially, (DAla2)GIP/xenin-8-Gln had equal or im-
proved beneficial effects on glycaemic status in high-fat mice.
Indeed, reductions in glucose levels were much more apparent
in mice treated with (DAla2)GIP/xenin-8-Gln during assessment
of the more-in-depth 24 h blood glucose profile. Interestingly,
significantly greater reductions in insulin-induced blood glucose
levels were observed in (DAla2)GIP/xenin-8-Gln- and
(DAla2)GIP-treated mice. This clearly points towards beneficial
effects of both treatments that are additional to effects on pan-
creatic beta cell function. This improvement of insulin action
was not a consequence of reduced adipose tissue mass. Thus,
it presumably reflects alleviation of glucotoxicity, or the actions
of GIP to improve insulin resistance [29, 37]. However, further
investigations, including euglycaemic–hyperinsulinaemic
clamps, glucose uptake and gene and protein expression studies,
are required to fully address the molecular mechanisms under-
pinning this benefit. Somewhat surprisingly, at the dose tested,
(DAla2)GIP/xenin-8-Gln had no effect on energy intake, al-
though similar observations have been reported previously with
xenin-based drugs [38]. This limited satiety effect presumably
reflects the requirement of supraphysiological doses of xenin to
impart appetite-suppressive effects [10]. However, it could also
be related to factors such as the palatability of the high-fat diet,
the age and strain of mice employed or the duration of the study.
As expected, a key component of the beneficial action of
(DAla2)GIP/xenin-8-Gln concerned the stimulation of beta
cell function [13, 29]. Circulating and glucose-induced plasma
insulin concentrations were significantly elevated compared
with those in lean control mice, despite non-fasting glucose
levels being similar. Moreover, the pancreatic insulin content
was persistently higher in (DAla2)GIP/xenin-8-Gln-treated
high-fat-fed mice. In agreement, pancreatic islet and beta cell
areas were increased in (DAla2)GIP/xenin-8-Gln-treated
mice, in line with the proliferative and anti-apoptotic beta cell
actions of (DAla2)GIP/xenin-8-Gln, as has previously been
reported for GIP [39, 40]. Consistent with our observations,
the positive actions of GIP on islet and beta cell architecture
have previously been shown to improve beta cell function and
glycaemic control in animal models of type 2 diabetes [41].
Interestingly, there is a recent suggestion that xenin may in-
hibit GLP-1 secretion under certain circumstances [42].
However, such observations still need to be fully confirmed
and the current findings would not indicate any obvious det-
rimental effects linked to reduced GLP-1 secretion or action
by (DAla2)GIP/xenin-8-Gln.Moreover, GIP is known to stim-
ulate GLP-1 secretion from the gut [43] as well as pancreatic
alpha cells [44], affording GIP/xenin hybrids a clear advan-
tage over xenin monotherapies. In keeping with improved
beta cell dynamics in (DAla2)GIP/xenin-8-Gln-treated mice,
the insulin-secretory and subsequent glucose-lowering effects
of native GIP were substantially enhanced in these mice. As
expected, the biological action of GIP was severely perturbed
in high-fat-fed mice, akin to the situation in patients with type
2 diabetes [4]. It would be more than reasonable to link a
major part of the positive therapeutic effects of (DAla2)GIP/
xenin-8-Gln directly to augmentation of GIP action, as previ-
ously observed with other xenin-related compounds [10, 38].
Thus, the main rationale for inclusion of the xenin component
of our novel hybrid peptide was essentially to enhance GIP-
mediated actions [10, 38]. However, normalisation of blood
glucose levels, as clearly demonstrated in both (DAla2)GIP-
and (DAla2)GIP/xenin-8-Gln-treated mice, has also been
shown to independently restore GIP insulin-secretory function
in type 2 diabetes [5, 6]. In addition, we have already confirmed
that xenin has significant glucose-lowering activity independent
of theGIP receptor [38]. Therefore, further studies are required to
systematically assess the direct and indirect beneficial effects of
(DAla2)GIP/xenin-8-Gln in restoring GIP action in type 2
diabetes.
Interestingly, both activation and inhibition of GIP receptors
has been postulated as a possible treatment option for type 2
diabetes and obesity [45]. Thus, GIP receptor agonism augments
beta cell-induced glucose-dependent insulin secretion, akin to
the actions of clinically approved GLP-1 mimetics [3]. This
approach is very encouraging given that the issue of GIP sensi-
tivity in type 2 diabetes is now being addressed. However, GIP
is also believed to play a role in lipid metabolism and fat depo-
sition [45]. Accordingly, GIP receptor antagonism can potential-
ly protect against or even reverse many of the obesity-associated
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abnormalities of type 2 diabetes [46–48]. Similar to the conun-
drum regarding the clinical use of GIP receptor agonists or an-
tagonists, both genetic knockout [49] and overexpression [50] of
GIP has been shown to protect against obesity and development
of diabetes. Taken together, this likely reflects the plasticity of
cellular pathways linked to the regulation of energy balance.
Nonetheless, it is clear from the current study that novel treat-
ment options aimed at overcoming GIP resistance in type 2
diabetes have therapeutic potential.
In conclusion, the present study has demonstrated that the
novel hybrid peptide analogue (DAla2)GIP/xenin-8-Gln has
an impressive profile of beneficial metabolic effects in high-
fat-fed mice, including improvement of glucose tolerance, in-
sulin resistance and pancreatic islet morphology. Importantly,
there was a clear augmentation of the biological action of
native GIP in high-fat-fed mice, suggestive of restored GIP
effectiveness by (DAla2)GIP/xenin-8-Gln. Further studies are
required to fully evaluate the molecular mechanisms and full
range of actions of (DAla2)GIP/xenin-8-Gln. However, it is
evident that this stable GIP/xenin hybrid may represent an
attractive potential new therapeutic for type 2 diabetes.
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